{
    "clinical_study": {
        "@rank": "152988", 
        "arm_group": [
            {
                "arm_group_label": "Lanthanum carbonate", 
                "arm_group_type": "Active Comparator", 
                "description": "Lanthanum carbonate 375mg~750 mg tid for 6 months"
            }, 
            {
                "arm_group_label": "Calcium carbonate", 
                "arm_group_type": "Active Comparator", 
                "description": "Calcium carbonate 500mg~1000 mg tid for 6 months"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare  the effect of lanthanum carbonate with calcium carbonate on serum FGF23 levels\n      in hemodialysis patients."
        }, 
        "brief_title": "The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Other Nonspecific Abnormal Serum Enzyme Levels", 
        "detailed_description": {
            "textblock": "The investigators enrolled patients on maintenance hemodialysis and randomized them to two\n      groups. One group will receive lanthanum carbonate and another group will receive calcium\n      carbonate. The investigators will compare serum FGF23 levels between two groups after they\n      receive above medication for 6 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age > 18 years old\n\n          -  Chronic renal failure on maintenance hemodialysis 3 times a week for at least 3\n             months  Serum calcium:8-10.5 mg/dL\n\n          -  Serum phosphate:3.5-6 mg/dL(before washout period)\n\n          -  Serum phosphate \u22676 mg/dL after washout period\n\n          -  Serum i-PTH: 150-600 pg/mL\n\n        Exclusion Criteria:\n\n          -  Diabetes mellitus\n\n          -  Post parathyroidectomy\n\n          -  Life expectancy< 6 months\n\n          -  Liver disease(hepatitis B,C or liver dysfunction)\n\n          -  Severe gastrointestinal disorders or other severe comorbidity\n\n          -  Poor compliance\n\n          -  Intolerance to lanthanum or calcium carbonate\n\n          -  Active infection\n\n          -  Malnutrition(serum albumin<3 g/dL or clinical assessment)\n\n          -  Kt/V< 1.2 (inadequate dialysis)\n\n          -  Serum phosphate>7.5 mg/dL after washout period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01845090", 
            "org_study_id": "SMHLANFGF23"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lanthanum carbonate", 
                "description": "the effect on serum FGF23", 
                "intervention_name": "Lanthanum carbonate", 
                "intervention_type": "Drug", 
                "other_name": "Fosrenol"
            }, 
            {
                "arm_group_label": "Calcium carbonate", 
                "description": "Calcium carbonate 500mg~1000 mg tid for 6 months", 
                "intervention_name": "Calcium Carbonate", 
                "intervention_type": "Drug", 
                "other_name": "TOP-CAL(CaCO3)"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Calcium, Dietary", 
                "Calcium Carbonate", 
                "Mitogens"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 1, 2013", 
        "location": {
            "contact": {
                "email": "ynk123.tw@yahoo.com.tw", 
                "last_name": "Yu-Ming Chang, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Taipei", 
                    "country": "Taiwan", 
                    "zip": "265"
                }, 
                "name": "Saint Mary's hospital-Lotung"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Compared the Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 With Calcium Carbonate in Hemodialysis Patients", 
        "overall_contact": {
            "email": "ynk123.tw@yahoo.com.tw", 
            "last_name": "Yu-Ming Chang, MD"
        }, 
        "overall_official": {
            "affiliation": "Saint Mary's hospital-Lotung", 
            "last_name": "Shih-Ching Tsai, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Taiwan: Department of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "serum level of fibroblast growth factor", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01845090"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Camillians Saint Mary's Hospital Luodong", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Camillians Saint Mary's Hospital Luodong", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2011"
    }
}